Ori-A-626

N/A

Report date: 2022/07/29 17:58:08

Base Information

Drug NameOri-A-626
Drug Alias NameOri-A-626Ori-A626OriA-626
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionTransmembrane protein PVRIG antagonists
TargetsTransmembrane protein PVRIG
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesOriCell Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A